UNSPSC 51313216: Cycliramine maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H19CLN2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J542BCR0IQ. The term cycliramine maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule cycliramine maleate under HS 29333999 and SITC 51574. As of Q4 2014, CYCLIRAMINE MALEATE remains US FDA's Preferred Term for this commodity. Cycliramine maleate bears US NLM identifiers UMLS ID C1880204 and NCI Concept Code C65355.

SMILES: CN1CCC(=C(C2CCC(CC2)CL)C3CCCCN3)CC1.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51313216 Cycliramine maleate is a Commodity code that nominally covers a single pharmaceutical agent, but recent state and local procurement activity under this code spans a much broader pharmaceutical and health-supply procurement landscape. State and local governments are using this code to solicit naloxone, over-the-counter products, generic pharmaceuticals, and specialized health-system drug inventories through competitive bidding and cooperative purchasing arrangements. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances managing pharmacy benefit programs for government employees and public health agencies. Work ranges from direct purchase of discrete pharmaceutical units with scheduled quarterly deliveries to comprehensive pharmaceutical supply agreements that require manufacturers to provide detailed product information, maintain relationships with authorized wholesalers, and comply with FDA and Drug Supply Chain Security Act requirements.

Recent activity clusters in Florida and the Upper Midwest, with the most visible opportunities originating from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with delivery to the Seminole County Community Health Building and responses due July 26, 2023. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) with proposals due March 26, 2026, to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with awarded vendors effective July 1, 2026 and performance penalties ranging from $200 to $1,500 per violation. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, signaling upstream strategic procurement activity before formal solicitation.